Al adhesion Cytosolic DNA-sensing pathway Cytokine-cytokine receptor interaction Toll-like receptor signaling pathway Complement and coagulation cascades Staphylococcus aureus infection Graft-versus-host disease Allograft rejection Leishmaniasis Toxoplasmosis Viral myocarditis Dilated cardiomyopathy Hypertrophic cardiomyopathy (HCM) Aldosterone-regulated sodium reabsorption Influenza A Variety II diabetes mellitus Carbohydrate digestion and absorption Form I diabetes mellitus Asthma Tuberculosis Antigen processing and presentation Phagosome Autoimmune thyroid illness Intestinal immune network for IgA production Chagas illness (American trypanosomiasis) Prion illnesses African trypanosomiasis two.six (0.031) ten (28.6) 2.0 (0.0206) 22 (21.4) 5.five (0.0246) 4 (11.four) 1.9 (0.0377) two.0 (0.0494) 2.9 (0.00379) 2.7 (0.0211) 2.six (0.031) 2.0 (0.0451) 1.7 (0.0435) 2.six (0.00392) 2.3 (0.00489) two.3 (0.00487) two.eight (0.00761) 1.7 (0.0308) two.5 (0.0185) 2.6 (0.0225) 19 (20.7) 15 (21.7) 16 (31.4) 11 (29.7) 10 (28.6) 15 (22.1) 24 (18.8) 19 (27.9) 22 (24.7) 21 (25.three) 13 (31.0) 29 (18.four) 13 (27.7) 12 (27.9) eight.2 (0.000269) ten.three (0.000274) 3.eight (0.000386) five.7 (0.000668) 3.7 (0.00131) six.9 (0.00152) 6.three (0.00233) 7 (17.1) six (21.four) 13 (7.TMPA 9) 8 (11.9) 11 (7.7) six (14.3) 6 (13.0) 4.0 (0.000283) 13 (eight.2) two.6 (0.0203) two.4 (0.0474) 13 (27.7) 11 (25.six) 4.7 (0.019) ten.four (two.66e-05) 9.6 (0.000159) 4.9 (0.00304) 3.4 (0.00759) five (9.eight) 8 (21.6) 7 (20.0) 7 (ten.three) 9 (7.0) two.9 (0.00457) two.five (0.0468) 2.7 (0.0389) 2.1 (0.048) 1.7 (0.046) two.six (0.00457) two.three (0.00467) 2.two (0.00904) 2.9 (0.00814) 16 (31.4) 10 (27.0) ten (28.6) 15 (22.1) 24 (18.eight) 19 (27.9) 22 (24.7) 20 (24.1) 13 (31.0) Combined RA vs (OA or NL) or (OA+NL) EF (q-value) # of DMGs ( ) 2.five (0.00266) two.5 (0.00741) 1.8 (0.0294) 1.6 (0.0287) 24 (27.0) 16 (27.six) 25 (19.four) 35 (17.six) 4.six (0.0202) two.3 (0.0231) 5 (9.6) 12 (4.8) OA+NL OA or NL RA vs OA+NL RA vs OA or NL EF (q-value) # of DMGs ( ) EF (q-value) # of DMGs ( ) six.five (1.91e-05) five.eight (0.0014) three.0 (0.0232) 12 (13.five) 7 (12.1) 8 (6.2) 2.three (0.00467) 2.three (0.0374) 1.8 (0.0343) 1.six (0.0321) 22 (24.7) 14 (24.1) 25 (19.four) 35 (17.six)KEGG pathways that happen to be located as substantially enriched (q 0.05) in 3 comparisons are shown. Eight pathways especially relevant to RA are placed within the top part of the table. Within every single section, the amount of substantial comparisons orders the pathways. If several pathways have the identical number of comparison then an typical q values is utilised for ordering. # denotes the amount of DMGs inside the selected pathway.Whitaker et al. Genome Medicine 2013, 5:40 http://genomemedicine/content/5/4/Page six ofTable 3 Gene ontology terms which might be enriched in two or much more sets of genesComparison name Comparison description Pathway name constructive regulation of ERK1 and ERK2 cascade proteinaceous extracellular matrix signal transduction extracellular matrix inflammatory response fibroblast growth factor receptor signaling’ MHC class II protein complex focal adhesion Rho guanyl-nucleotide exchange issue activity regulation of Rho protein signal transduction constructive regulation of inflammatory response cell adhesion extracellular area extracellular space immune response plasma membrane Z disc scavenger receptor activity odontogenesis integral to plasma membrane multicellular organismal improvement structural molecule activity positive regulation of cell proliferation positive regulation of interferon-gamma production skeletal muscle contraction sarcolemma structural constituent of muscle a.Isatuximab (anti-CD38) PMID:23509865
